Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Suramin Inhibits Cullin-Ring E3 Ubiquitin Ligases

Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds

The Functions and Properties of Cullin-5, a Potential Therapeutic Target for Cancers.

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate–mediated regulation of cullin–RING ligase and sensitize cancer cells to MLN4924/pevonedistat

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

Suramin Targets the Conserved Ligand-Binding Pocket of Human Raf1 Kinase Inhibitory Protein

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

Cullin-RING Ligases as attractive anti-cancer targets.

UBE2G1 Governs the Destruction of Cereblon Neomorphic Substrates

UBE2G1 governs the destruction of cereblon neomorphic substrates.

Inositol hexakisphosphate (IP6) generated by IP5K mediates cullin-COP9 signalosome interactions and CRL function

Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.

The CRL3KCTD10 ubiquitin ligase–USP18 axis coordinately regulates cystine uptake and ferroptosis by modulating SLC7A11

Radiosensitization of Cancer Cells by Inactivation of Cullin-Ring E3 Ubiquitin Ligases

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity

E2 Enzyme Inhibition by Stabilization of a Low-Affinity Interface with Ubiquitin.

SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes.

Insights into the Allosteric Inhibition of the SUMO E2 Enzyme Ubc9.

Suramin: an anticancer drug with a unique mechanism of action.

A Potent Small-Molecule Inhibitor of the DCN1-UBC12 Interaction That Selectively Blocks Cullin 3 Neddylation